This study aimed to compare treatment outcomes between first-generation EGFR-TKIs combined with low-dose bevacizumab and osimertinib monotherapy in previously untreated patients with advanced EGFR-mutated NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.